Related Experiment Video
Updated: Jun 16, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Management of chronic kidney disease: what is the evidence?
1Department of Internal Medicine, Division of Nephrology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA. gbrosnahan@uams.edu
Insights
Chronic kidney disease (CKD) significantly increases cardiovascular risk. This review examines guidelines for managing CKD-related cardiovascular disease, focusing on hypertension, dyslipidemia, anemia, and mineral bone disorders.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Chronic kidney disease (CKD) is a major risk factor for cardiovascular events and mortality.
- Cardiovascular disease (CVD) in CKD is linked to hypertension, dyslipidemia, anemia, vascular calcification, and secondary hyperparathyroidism.
Purpose of the Study:
- To review current clinical guidelines for managing cardiovascular risk in CKD patients.
- To evaluate the evidence supporting treatment recommendations for key risk factors.
Main Methods:
- Systematic review of clinical trials and existing guidelines.
- Analysis of evidence regarding blood pressure targets, renin-angiotensin system blockade, dyslipidemia treatment, anemia management, and mineral bone disorders.
Main Results:
- Guidelines address blood pressure goals, proteinuria reduction, and dyslipidemia management in CKD.
- Evidence supports erythropoietin use for anemia but with varying hemoglobin targets.
- Phosphate binders may benefit secondary hyperparathyroidism; sodium bicarbonate may slow CKD progression.
Conclusions:
- Managing modifiable risk factors is crucial for reducing cardiovascular events in CKD.
- Evidence strength varies for different interventions, necessitating careful guideline application.
- Further research is needed to optimize treatment strategies for CKD-associated cardiovascular disease.
Abstract:
Chronic kidney disease (CKD) is a strong risk factor for cardiovascular events and death. Hypertension, dyslipidemia, anemia, vascular calcification, and secondary hyperparathyroidism have all been implicated in the pathogenesis of cardiovascular disease associated with CKD. Numerous trials have been performed assessing the effects of modifying these risk factors on cardiovascular events and on the progression to end-stage renal disease. Many guidelines have been issued. In this article we review the guidelines and the strength of evidence supporting them. Specifically, we discuss blood pressure goals for patients with CKD, the role of renin-angiotensin system blocking agents for blood pressure control and proteinuria reduction, and the evidence for treatment recommendations of dyslipidemia. We review the trials addressing risks and benefits of different hemoglobin targets for treatment of anemia with erythropoietin. The use of phosphate-binding drugs to prevent and treat secondary hyperparathyroidism is likely beneficial, but few data support the use of vitamin D compounds. Supplementation with sodium bicarbonate may be an inexpensive treatment to retard progression to end-stage renal disease. The article concludes with a discussion of the case vignette presented in the previous article.
Related Concept Videos
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction
Acute Kidney Injury VI: Nursing Management
Nephrotic Syndrome III : Nursing Management
Acute Kidney Injury V: Interprofessional Care